Zomedica sees Q4 rev $6.0-6.2M (+46-51% YoY); FY rev up ~360%

Zomedica Corp.

2023-FY EPS reported -$0.02 revenue$18,930,000

Q4 2022 revenue expected $6.0-$6.2M, +46-51% vs Q4 2021, driven by PulseVet and Assisi.
Full-year 2022 revenue expected $18.6-$18.9M, +354-361% over 2021.
Gross margin for FY 2022 expected ~72%.
Cash, cash equivalents and available-for-sale securities ~$156M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zomedica Corp. reported fourth quarter and year ended 2022 results: revenue approximately $6.0-$6.2 million.

Period: fourth quarter and year ended 2022
Revenue: approximately $6.0-$6.2 million
Result: preliminary results

Exact text from the filing

Revenue for the fourth quarter of 2022 is expected to be approximately $6.0-$6.2 million

View on SEC.gov

Browse all earnings releases →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-23-001545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.